

Gwenaelle Gravis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3892882/publications.pdf>

Version: 2024-02-01

55
papers

6,277
citations

257450

24
h-index

155660

55
g-index

59
all docs

59
docs citations

59
times ranked

6083
citing authors

#	ARTICLE	IF	CITATIONS
1	External validation of the computerized analysis of TRUS of the prostate with the ANNA/C-TRUS system: a potential role of artificial intelligence for improving prostate cancer detection. <i>World Journal of Urology</i> , 2023, 41, 619-625.	2.2	8
2	Comparison Between Micro-Ultrasound and Multiparametric MRI Regarding the Correct Identification of Prostate Cancer Lesions. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e339-e345.	1.9	6
3	Quality and Quantity: Evaluating Tumor Biology Alongside Novel Imaging on Diagnosis of Metastatic Hormone-sensitive Prostate Cancer. <i>European Urology</i> , 2022, 81, 437-439.	1.9	0
4	Self-reported functional assessment after treatment for prostate cancer: 5-year results of the prospective cohort VICAN. <i>Future Oncology</i> , 2022, , .	2.4	0
5	Efficacy and safety of nivolumab in renal cell carcinoma patients with BONE metastases: Results of the GETUG: AFU 26 nivoren multicenter phase II study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 342-342.	1.6	1
6	The Psychological Distress of Cancer Patients following the COVID-19 Pandemic First Lockdown: Results from a Large French Survey. <i>Cancers</i> , 2022, 14, 1794.	3.7	7
7	Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 2013-2022.	1.6	75
8	Nivolumab, nivolumab+ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 612-624.	10.7	66
9	Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2x2 factorial design. <i>Lancet</i> , The, 2022, 399, 1695-1707.	13.7	261
10	Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study. <i>European Urology</i> , 2022, 82, 22-30.	1.9	34
11	A non-inferiority randomized phase III trial of standard immunotherapy versus reduced dose intensity in responding patients with metastatic cancer: MOIO study.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS2674-TPS2674.	1.6	3
12	Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses. <i>European Urology</i> , 2021, 79, 214-221.	1.9	130
13	Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Access Program. <i>European Journal of Cancer</i> , 2021, 142, 102-111.	2.8	35
14	Gastrointestinal Metastases From Primary Renal Cell Cancer: A Single Center Review. <i>Frontiers in Oncology</i> , 2021, 11, 644301.	2.8	3
15	Feasibility and first results of digital patient-reported outcomes measures (PROMs) data collection for patients with localized prostate cancer at diagnosis.. <i>Journal of Clinical Oncology</i> , 2021, 39, 12071-12071.	1.6	0
16	Impact of sarcopenia status of muscle-invasive bladder cancer patients on kidney function after neoadjuvant chemotherapy. <i>Minerva Urology and Nephrology</i> , 2021, 73, 215-224.	2.5	4
17	Phase 2 study of retifanlimab (INCMGA00012) in patients (pts) with selected solid tumors (POD1UM-203).. <i>Journal of Clinical Oncology</i> , 2021, 39, 2571-2571.	1.6	4
18	Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial. <i>European Urology Oncology</i> , 2021, 4, 456-463.	5.4	18

#	ARTICLE	IF	CITATIONS
19	Prognostic Risk Classification for Biochemical Relapse-Free Survival in Oligometastatic Recurrent Prostate Cancer Determined by Choline PET. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 346-353.	1.9	1
20	Primary Renal Tumour Response in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma: Results from the GETUG-AFU 26 NIVOREN Trial. <i>European Urology</i> , 2021, 80, 325-329.	1.9	16
21	Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 554-562.	1.9	6
22	Cost-effectiveness Analysis of Innovative Therapy for Patients with Newly Diagnosed Hormone-Sensitive Metastatic Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e326-e333.	1.9	7
23	Endoscopic Ultrasound-Guided Radiofrequency Ablation as an Future Alternative to Pancreatectomy for Pancreatic Metastases from Renal Cell Carcinoma: A Prospective Study. <i>Cancers</i> , 2021, 13, 5267.	3.7	10
24	Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 295-303.e3.	1.9	12
25	Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge?. <i>European Urology</i> , 2020, 77, 761-763.	1.9	51
26	Deterioration of Sexual Health in Cancer Survivors Five Years after Diagnosis: Data from the French National Prospective VICAN Survey. <i>Cancers</i> , 2020, 12, 3453.	3.7	12
27	A combined biological and clinical rationale for evaluating metastasis directed therapy in the management of oligometastatic prostate cancer. <i>Radiotherapy and Oncology</i> , 2020, 152, 80-88.	0.6	9
28	Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial. <i>Cancer Cell</i> , 2020, 38, 489-499.e3.	16.8	216
29	Reply to Nirmish Singla and Vitaly Margulis's Letter to the Editor re: Geraldine Pignot, Antoine Thiery-Vuillemin, Jochen Walz, et al. Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge? <i>Eur Urol</i> . In press. https://doi.org/10.1016/j.eururo.2019.12.018 . The Next Surgical Frontier in Kidney Cancer: Nephrectomy After Immune Checkpoint Inhibition. <i>European Urology</i> , 2020, 78, e81-e82.	1.9	2
30	Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy. <i>JAMA Oncology</i> , 2019, 5, 623.	7.1	25
31	Systemic treatment for metastatic prostate cancer. <i>Asian Journal of Urology</i> , 2019, 6, 162-168.	1.2	31
32	The Biology of Oligometastatic Prostate Cancer: A Different Beast than Polymetastatic Prostate Cancer. <i>European Urology Focus</i> , 2019, 5, 117-118.	3.1	7
33	Adaptation and validation of the memorial anxiety scale for prostate cancer (MAX-PC) in a sample of French men. <i>Journal of Patient-Reported Outcomes</i> , 2019, 3, 60.	1.9	3
34	Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. <i>European Urology</i> , 2018, 73, 847-855.	1.9	174
35	Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial. <i>European Urology</i> , 2018, 73, 696-703.	1.9	45
36	Impact of Patient- and Clinician-Reported Cumulative Toxicity on Quality of Life in Patients With Metastatic Castration-Naïve Prostate Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 1481-1488.	4.9	13

#	ARTICLE	IF	CITATIONS
37	Unexpected response to cisplatin rechallenge after immune checkpoint inhibitors in patients with metastatic urothelial carcinoma refractory to platinum regimen. <i>European Journal of Cancer</i> , 2018, 104, 236-238.	2.8	18
38	Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study. <i>European Journal of Cancer</i> , 2017, 83, 194-202.	2.8	14
39	Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature. <i>Cancer Treatment Reviews</i> , 2017, 55, 211-217.	7.7	20
40	Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. <i>Lancet Oncology</i> , The, 2016, 17, 243-256.	10.7	361
41	Effect of glandular metastases on overall survival of patients with metastatic clear cell renal cell carcinoma in the antiangiogenic therapy era. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 167.e17-167.e23.	1.6	22
42	Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial. <i>European Urology</i> , 2016, 70, 256-262.	1.9	355
43	Radiation therapy following targeted therapy in oligometastatic renal cell carcinoma. <i>Molecular and Clinical Oncology</i> , 2015, 3, 1248-1250.	1.0	5
44	Which one is a valuable surrogate for predicting survival between Tomita and Tokuhashi scores in patients with spinal metastases? A meta-analysis for diagnostic test accuracy and individual participant data analysis. <i>Journal of Neuro-Oncology</i> , 2015, 123, 267-275.	2.9	36
45	Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. <i>Lancet Oncology</i> , The, 2015, 16, 787-794.	10.7	206
46	Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model. <i>European Urology</i> , 2015, 68, 196-204.	1.9	102
47	Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France. <i>BMC Cancer</i> , 2015, 15, 222.	2.6	20
48	Reassessment of scoring systems and prognostic factors for metastatic spinal cord compression. <i>Spine Journal</i> , 2015, 15, 944-950.	1.3	68
49	Patients' self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15). <i>European Journal of Cancer</i> , 2014, 50, 953-962.	2.8	63
50	Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 149-158.	10.7	586
51	Major response with sorafenib in advanced renal cell carcinoma after 14 years of follow-up. <i>World Journal of Surgical Oncology</i> , 2013, 11, 243.	1.9	4
52	Complete Remission With Tyrosine Kinase Inhibitors in Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 482-487.	1.6	156
53	A phase III trial of docetaxel+estramustine in high-risk localised prostate cancer: A planned analysis of response, toxicity and quality of life in the GETUG 12 trial. <i>European Journal of Cancer</i> , 2012, 48, 209-217.	2.8	47
54	Full access to medical records does not modify anxiety in cancer patients. <i>Cancer</i> , 2011, 117, 4796-4804.	4.1	28

#	ARTICLE	IF	CITATIONS
55	Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. <i>Lancet, The</i> , 2010, 376, 1147-1154.	13.7	2,857